DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...
Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on ...
Zacks Investment Research on MSN
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong ...
A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump.
This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback